SCHEMBL24329491

SCHEMBL24329491

CC(=O)c1ccc(CO)c(F)c1

nearest known ligand 0.59

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.59
MAOB P27338 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.41
HTT P42858 1/20 0.41
CES2 O00748 1/20 0.41
CES1 P23141 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 1/20 0.41
MAOA P21397 1/20 0.41
KIF11 P52732 1/20 0.40
NPC1 O15118 1/20 0.40
RAB9A P51151 1/20 0.40
GAA P10253 1/20 0.40
POLB P06746 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6180535 0.86 MAOB (0.51) PKMMAOBL3MBTL1HTTCES2
SCHEMBL15985419 0.82 PKM (0.72) PKMMAOBHTTKMT2AALDH1A1
SCHEMBL7513592 0.82 EPHX2 (0.51) L3MBTL1HTTCES2CES1ALDH1A1
SCHEMBL18073734 0.82 PKM (0.71) PKML3MBTL1HTTKMT2AALDH1A1
SCHEMBL31387892 0.81 MAOB (0.48) PKMMAOBL3MBTL1KMT2AALDH1A1
SCHEMBL22491940 0.81 MAOB (0.48) PKMMAOBL3MBTL1KMT2AALDH1A1
SCHEMBL12438206 0.81 GAA (0.50) PKMMAOBCES2CES1GAA
SCHEMBL30474148 0.81 PARP1 (0.46) PKMMAOBCES2CES1KMT2A
SCHEMBL27150109 0.80 DPP4 (0.50) HTTKMT2AALDH1A1MAPTHPGD
SCHEMBL18290649 0.80 MAOB (0.47) PKMMAOBL3MBTL1HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF HANGZHOU ZHONGMEIHUADONG PHARMACEUTICAL CO., LTD. (CN) 2025-08-21 US disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
EP-4227299-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. (CN) 2023-08-16 EP disclosed
CN-116348464-A Benzimidazolone GLP-1 receptor agonists and uses thereof 杭州中美华东制药有限公司 2023-06-27 CN disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 WO disclosed
WO-2022078152-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF 杭州中美华东制药有限公司 2022-04-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250263402-A1 BENZIMIDAZOLONE GLP-1 RECEPTOR AGONIST AND USE THEREOF GLP1R, GIPR, GCGR PKM 1611/4885MAOB 3569/4885L3MBTL1 2314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.